Venetoclax Combined With Chemotherapy in Pediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Pediatric Blood & Cancer · 2025-06 · 72 (6)
DOI: 10.1002/pbc.31630 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 10.03.2025. Verfasst von Andrew E Place und 21 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AbbVie, Genentech.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and although many patients respond to induction therapy, those who relapse or have refractory disease face a poor prognosis. Venetoclax has promising preclinical and clinical activity in ALL. Here, we report the safety and preliminary efficacy of venetoclax combined with chemotherapy in pediatric and adolescent/young adult patients with relapsed/refractory ALL. Procedure This phase 1, open‐label, two‐part, multicenter study evaluated venetoclax combined with chemotherapy in pediatric and adolescent/young adult patients (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, USA.
- St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
- Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Seattle Children's Hospital, Cancer and Blood Disorders Center, Seattle, Washington, USA.
- Queensland Children's Hospital, South Brisbane, QLD, Australia.
- Universitätsklinikum Schleswig-Holstein, Kiel, Germany.
ORCID-Profile: Andrew E Place, Seth E Karol, Todd M Cooper, Gunnar Cario, Jean-Pierre Bourquin, Mignon L Loh
Förderung
- AbbVie
- Genentech
Zitieren
APA
Place, A. E., Karol, S. E., Forlenza, C. J., Cooper, T. M., Fraser, C., Cario, G., O'Brien, M. M., Gerber, N. U., Bourquin, J. P., Reinhardt, D., Rubnitz, J. E., Opferman, J. T., Sunkersett, G., Onishi, M., Dunshee, D. R., Chen, X., Unnebrink, K., Vishwamitra, D., Dunbar, F., …, & Loh, M. L. (2025). Venetoclax Combined With Chemotherapy in Pediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. Pediatric Blood & Cancer, 72(6). https://doi.org/10.1002/pbc.31630
Vancouver
Place AE, Karol SE, Forlenza CJ, Cooper TM, Fraser C, Cario G, et al. Venetoclax Combined With Chemotherapy in Pediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. Pediatric Blood & Cancer. 2025;72(6). doi:10.1002/pbc.31630
BibTeX
@article{Place2025,
author = {Place, Andrew E and Karol, Seth E and Forlenza, Christopher J and Cooper, Todd M and Fraser, Christopher and Cario, Gunnar and O'Brien, Maureen M and Gerber, Nicolas U and Bourquin, Jean-Pierre and Reinhardt, Dirk and Rubnitz, Jeffrey E and Opferman, Joseph T and Sunkersett, Gauri and Onishi, Maika and Dunshee, Diana R and Chen, Xin and Unnebrink, Kristina and Vishwamitra, Deeksha and Dunbar, Fengjiao and Badawi, Mohamed and Ross, Jeremy A and Loh, Mignon L},
title = {Venetoclax Combined With Chemotherapy in Pediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia},
journal = {Pediatric Blood & Cancer},
year = {2025},
volume = {72},
number = {6},
doi = {10.1002/pbc.31630}
}
EUVIMED